SLC2A1 and central nervous system cancer: To evaluate whether our in vivo results widely extend to various types of gliomas with diffuse invasion, we collected samples from 66 patients with confirmed gliomas including nearly all subtypes of gliomas (Supplementary Table S5), and then performed IHC for GLUT1 (Figure 5G).